Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study

Background: Use of continuous glucose monitoring (CGM) systems is being rapidly adopted as standard of care for insulin-requiring patients with diabetes. The PROMISE study (NCT03808376) evaluated the accuracy and safety of the next-generation implantable Eversense CGM system for up to 180 days. Meth...

Descripción completa

Detalles Bibliográficos
Autores principales: Garg, Satish K., Liljenquist, David, Bode, Bruce, Christiansen, Mark P., Bailey, Timothy S., Brazg, Ronald L., Denham, Douglas S., Chang, Anna R., Akturk, Halis Kaan, Dehennis, Andrew, Tweden, Katherine S., Kaufman, Francine R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817689/
https://www.ncbi.nlm.nih.gov/pubmed/34515521
http://dx.doi.org/10.1089/dia.2021.0182

Ejemplares similares

Ejemplares similares